![](https://insights.axtria.com/hubfs/Everest%20Group%20Life%20Sciences%20Digital%20Services%20Specialists.png)
Trending
Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024
We’re proud to have been named a Leader in the Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Report. Everest Group classified ...
![From Chaos to Cohesion](https://insights.axtria.com/hs-fs/hubfs/From%20Chaos%20to%20Cohesion-1.jpg?width=234&height=327&name=From%20Chaos%20to%20Cohesion-1.jpg)
Cancer Drugs
![Pharma’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy](https://insights.axtria.com/hubfs/Axtria-2023/solutions/AstraZenecas-Bold-And-Potentially-Risky-New-Cancer-Drug-RD-Portfolio-Strategy%20%283%29.jpg)
Pharma’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy
Many pharma companies have begun shifting their R&D portfolios to the development of new cancer drugs. A pharma company recently announced a bold new cancer drug R&D portfolio strategy where the company will focus on early-stage cancers over late-stage (advanced) cancers for new drug development. This shift in focus goes against the standard target development paradigm where companies ...